Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Rongchang Biotech: The dual-antibody ADC drug RC288 has received the clinical trial approval notice.
People’s Finance News, April 1. Rongchang Biotech (688331) announced on April 1 that it received a “Notice of Approval of a Drug Clinical Trial” issued and approved by the National Medical Products Administration. The company’s independently developed dual-antibody ADC drug RC288 monotherapy for Phase I/IIa clinical trials treating locally advanced unresectable or metastatic malignant solid tumors has been approved.